NCT00130923View on ClinicalTrials.gov

Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

June 30, 2009

Study Completion Date

July 31, 2010

Conditions
SchizophreniaPsychotic DisordersSubstance AbuseAlcohol Abuse
Interventions
DRUG

Risperidone Long Acting

Dose 25.00, 37.50 or 50.00 mg q two weeks

DRUG

oral risperidone

0.50-6.00 mg oral risperidone daily

Trial Locations (8)

29203

University of South Carolina, Columbia

33136

JMH Mental Health Center, University of Miami, Miami

63110

Washington University School of Medicine, St Louis

64108

School of Pharmacy, Univ. of Missouri Kansas City, Kansas City

03766

West Central Behavioral Health, Lebanon

03101

Mental Health Center of Greater Manchester, Manchester

03060

Center for Psychiatric Advancement, Nashua

05009

White River Junction Veterans Admininistration Medical Center, White River Junction

All Listed Sponsors
collaborator

Janssen, LP

INDUSTRY

lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT00130923 - Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder | Biotech Hunter | Biotech Hunter